Published in:
Open Access
01-12-2019 | Dementia | Research article
Validation of Addenbrooke’s cognitive examination III for detecting mild cognitive impairment and dementia in Japan
Authors:
Shintaro Takenoshita, Seishi Terada, Hidenori Yoshida, Megumi Yamaguchi, Mayumi Yabe, Nao Imai, Makiko Horiuchi, Tomoko Miki, Osamu Yokota, Norihito Yamada
Published in:
BMC Geriatrics
|
Issue 1/2019
Login to get access
Abstract
Background
Early detection of mild cognitive impairment (MCI) and dementia is very important to begin appropriate treatment promptly and to prevent disease exacerbation. We investigated the screening accuracy of the Japanese version of Addenbrooke’s Cognitive Examination III (ACE-III) to diagnose MCI and dementia.
Methods
The original ACE-III was translated and adapted to Japanese. It was then administered to a Japanese population. The Hasegawa Dementia Scale-revised (HDS-R) and Mini-mental State Examination (MMSE) were also applied to evaluate cognitive dysfunction. In total, 389 subjects (dementia = 178, MCI = 137, controls = 73) took part in our study.
Results
The optimal ACE-III cut-off scores to detect MCI and dementia were 88/89 (sensitivity 0.77, specificity 0.92) and 75/76 (sensitivity 0.82, specificity 0.90), respectively. ACE-III was superior to HDS-R and MMSE in the detection of MCI or dementia. The internal consistency, test-retest reliability, and inter-rater reliability of ACE-III were excellent.
Conclusions
ACE-III is a useful cognitive test to detect MCI and dementia. ACE-III may be widely useful in clinical practice.